Clinical trials: in Romania
Dry Eye Disease (DED), Graves Ophthalmopathy
Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients With Graves Disease
This prospective, interventional, randomized, controlled, double-blind clinical study evaluates the effect of Low-Level Light Therapy (LLLT) delivered by a polychromatic periocular mask (Eye-light®️) versus a sham device in…
- Trial name
- LLLT-Graves (NCT07332988)
- Testing
- Low Light Level therapy
- Where
- Romania
- Volunteers
- 30 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Meningitis, Meningitis/Encephalitis
Optic Nerve Ultrasound for Assessing Cerebral Inflammation and Intracranial Hypertension in Cerebral Pathologies
Timely detection of signs of raised intracranial pressure or persistent inflammation within the meninges can expedite therapeutic decisions improving the prognosis of patients with brain damage.
- Conditions
- Meningitis, Meningitis/Encephalitis, Stroke, Ultrasound
- Trial name
- EICON (NCT07332234)
- Testing
- Optic Nerve Sheath Diameter
- Where
- 2 sites in Romania
- Volunteers
- 200 people
- Sponsor
- Spitalul Clinic de Boli Infecțioase și tropicale "Dr. Victor Babeș"
Carcinoma, Non-Small -Cell Lung
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®).
- Trial name
- NCT06908304
- Testing
- 6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel
- Where
- 15 sites in Poland, Romania and 2 more
- Volunteers
- 300 people
- Sponsor
- Maia Biotechnology
Melanoma
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.
- Trial name
- NCT06054555
- Testing
- ABP 206, Nivolumab
- Where
- 180 sites in United States, Argentina and 29 more
- Volunteers
- 633 people
- Sponsor
- Amgen
Hepatocellular Carcinoma, Hepatoma
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior…
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma
- Trial name
- NCT04567615
- Testing
- Nivolumab, Relatlimab
- Where
- 65 sites in Argentina, Brazil and 15 more
- Volunteers
- 266 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.
- Trial name
- RELATIVITY-098 (NCT05002569)
- Testing
- Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination
- Where
- 184 sites in United States, Argentina and 23 more
- Volunteers
- 1,093 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor, Adult
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4.
- Trial name
- NCT06265727
- Testing
- CRB-701, Anti-PD-1
- Where
- 41 sites in United States, France and 5 more
- Volunteers
- 348 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Primary Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to…
- Trial name
- PERSEUS (NCT04458051)
- Testing
- Tolebrutinib
- Where
- 277 sites in United States, Argentina and 40 more
- Volunteers
- 767 people
- Sponsor
- Sanofi
Chronic Kidney Disease
Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis
The primary objective of this study is to demonstrate the superiority of MCI-196 over placebo and non-inferiority with simvastatin in reducing serum low-density lipoprotein (LDL)-cholesterol in subjects with chronic kidney…
- Trial name
- NCT00858637
- Testing
- MCI-196, Simvastatin
- Where
- 39 sites in Belarus, Bulgaria and 11 more
- Volunteers
- 260 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the safety and efficacy of MP-513 in combination with Metformin in patients with type 2 diabetes for 24 weeks administration and to evaluate the safety and efficacy of MP-513 in…
- Trial name
- NCT00971243
- Testing
- MP-513 Lowest Dose and Metformin, MP-513 Low Dose and Metformin, MP-513 Medium Dose and Metformin
- Where
- 44 sites in Denmark, Germany and 5 more
- Volunteers
- 448 people
- Sponsor
- Tanabe Pharma Corporation
Stroke, Ischemic
Vojta Therapy Versus Conservative Therapy for Patients With Stroke
Main hypothesis: Vojta Therapy shows significantly better results in regaining functional independence for patients with ischemic stroke than the Conservative Therapy The present study wishes to bring evidence that Vojta Therapy…
- Trial name
- NCT07307001
- Testing
- Vojta therapy, Conservative therapy
- Where
- Romania
- Volunteers
- 150 people
- Sponsor
- Lucaci Doru Nicolae
Non Small Cell Lung Cancer
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating…
- Trial name
- CheckMate 816 (NCT02998528)
- Testing
- Nivolumab, Cisplatin, Vinorelbine
- Where
- 138 sites in United States, Argentina and 13 more
- Volunteers
- 505 people
- Sponsor
- Bristol-Myers Squibb
Stroke, Stroke Rehabilitation
Personalised Health Motor and Cognitive Assistance System for RehAbilitation (PHRASE)
This study is a multicentric randomized controlled trial evaluating the effectiveness of digital technology, specifically a smartphone with integrated VR-and AR-based intervention, for at-home rehabilitation after stroke.
- Conditions
- Stroke, Stroke Rehabilitation, Chronic Stroke Patients, Post Stroke Recovery
- Trial name
- PHRASE-2024 (NCT06885502)
- Testing
- RGS
- Where
- 2 sites in Romania, Spain
- Volunteers
- 70 people
- Sponsor
- Eodyne Systems SL
Small Cell Lung Cancer (SCLC)
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).
- Trial name
- DeLLphi-304 (NCT05740566)
- Testing
- Tarlatamab, Lurbinectedin, Topotecan
- Where
- 223 sites in United States, Argentina and 29 more
- Volunteers
- 509 people
- Sponsor
- Amgen
Iatrogenic Withdrawal Syndrome
IWS Diagnosis Criteria Consensus
This is an International Delphi Consensus on the Definition and Diagnosis of Iatrogenic Withdrawal Syndrome in adult critically ill patients. It involves the anonymous completion of a questionnaire using a 7-point Likert scale.
- Trial name
- NCT07316894
- Testing
- ICU, Anesthesiology and Psychiatry specialists consensus on the diagnosis of IWS.
- Where
- Romania
- Volunteers
- 120 people
- Sponsor
- ELIAS Emergency University Hospital
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)
Primary Objectives: 1. The primary efficacy objective is to assess the efficacy of 52 weeks of open-label treatment with HZN-825 in participants with diffuse cutaneous systemic sclerosis, as measured by change from both baselines…
- Trial name
- NCT05626751
- Testing
- HZN-825
- Where
- 65 sites in United States, Argentina and 13 more
- Volunteers
- 174 people
- Sponsor
- Amgen
Dry Eye, Meibomian Gland Dysfunction (Disorder)
Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients Undergoing Cataract Surgery
This randomized, controlled clinical trial investigates the perioperative use of low-level light therapy (LLLT) to prevent or reduce signs and symptoms of dry eye disease (DED) in patients undergoing cataract surgery.
- Conditions
- Dry Eye, Meibomian Gland Dysfunction (Disorder), Ocular Surface Disease
- Trial name
- LLLT-Cataract (NCT07067294)
- Testing
- Low-Level Light Therapy
- Where
- Romania
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Coronary Artery Disease, Total Occlusion of Coronary Artery
Drug-coated Balloon in de Novo Chronic Total Occlusions
The CTO-DENOVO study is a multicenter registry of consecutive patients with de novo coronary chronic total occlusions (CTO) undergoing successful CTO recanalization with the use of drug-coated balloon (DCB)-only strategy.
- Trial name
- CTO-DENOVO (NCT05977842)
- Testing
- CTO PCI using DCB-only strategy
- Where
- 35 sites in Austria, Belgium and 10 more
- Volunteers
- 309 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Ulcerative Colitis
An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
The purpose of this study is to evaluate the long-term safety and efficacy of RPC1063 in participants with moderately to severely active ulcerative colitis.
- Trial name
- NCT02531126
- Testing
- RPC1063
- Where
- 41 sites in United States, Australia and 18 more
- Volunteers
- 877 people
- Sponsor
- Celgene
Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular endothelial growth factor (VEGF) receptor, programmed death receptor ligands 1 (PD-L1) expression…
- Trial name
- FIRST (NCT03602859)
- Testing
- Niraparib, Dostarlimab (TSR-042), Standard of care
- Where
- 182 sites in United States, Belarus and 17 more
- Volunteers
- 1,400 people
- Sponsor
- Tesaro, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.